Repository logo
 

Oesophageal cancer.

Simple item page
cam.issuedOnline2017-07-27
dc.contributor.authorSmyth, Elizabeth C
dc.contributor.authorLagergren, Jesper
dc.contributor.authorFitzgerald, Rebecca C
dc.contributor.authorLordick, Florian
dc.contributor.authorShah, Manish A
dc.contributor.authorLagergren, Pernilla
dc.contributor.authorCunningham, David
dc.contributor.orcidFitzgerald, Rebecca [0000-0002-3434-3568]
dc.date.accessioned2018-09-05T12:49:40Z
dc.date.available2018-09-05T12:49:40Z
dc.date.issued2017-07-27
dc.description.abstractOesophageal cancer is the sixth most common cause of cancer-related death worldwide and is therefore a major global health challenge. The two major subtypes of oesophageal cancer are oesophageal squamous cell carcinoma (OSCC) and oesophageal adenocarcinoma (OAC), which are epidemiologically and biologically distinct. OSCC accounts for 90% of all cases of oesophageal cancer globally and is highly prevalent in the East, East Africa and South America. OAC is more common in developed countries than in developing countries. Preneoplastic lesions are identifiable for both OSCC and OAC; these are frequently amenable to endoscopic ablative therapies. Most patients with oesophageal cancer require extensive treatment, including chemotherapy, chemoradiotherapy and/or surgical resection. Patients with advanced or metastatic oesophageal cancer are treated with palliative chemotherapy; those who are human epidermal growth factor receptor 2 (HER2)-positive may also benefit from trastuzumab treatment. Immuno-oncology therapies have also shown promising early results in OSCC and OAC. In this Primer, we review state-of-the-art knowledge on the biology and treatment of oesophageal cancer, including screening, endoscopic ablative therapies and emerging molecular targets, and we discuss best practices in chemotherapy, chemoradiotherapy, surgery and the maintenance of patient quality of life.
dc.format.mediumElectronic
dc.identifier.doi10.17863/CAM.26971
dc.identifier.eissn2056-676X
dc.identifier.issn2056-676X
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/279600
dc.languageeng
dc.language.isoeng
dc.subjectAdenocarcinoma
dc.subjectAfrica, Eastern
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAntineoplastic Agents, Immunological
dc.subjectCarcinoma, Squamous Cell
dc.subjectChemoradiotherapy
dc.subjectEndoscopy, Digestive System
dc.subjectEsophageal Neoplasms
dc.subjectEsophageal Squamous Cell Carcinoma
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPrognosis
dc.subjectReceptor, ErbB-2
dc.subjectSouth America
dc.subjectSurvival Rate
dc.subjectTrastuzumab
dc.subjectTreatment Outcome
dc.titleOesophageal cancer.
dc.typeArticle
dcterms.dateAccepted2017-06-08
prism.publicationDate2017
prism.publicationNameNat Rev Dis Primers
prism.startingPage17048
prism.volume3
pubs.funder-project-idCancer Research Uk (None)
rioxxterms.licenseref.startdate2017-07-27
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.typeJournal Article/Review
rioxxterms.versionAM
rioxxterms.versionofrecord10.1038/nrdp.2017.48

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
NRDP_17_012oesophageal cancer_CLEAN 22 06 2017.docx
Size:
427.9 KB
Format:
Microsoft Word XML
Description:
Accepted version
Licence
http://www.rioxx.net/licenses/all-rights-reserved
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
DepositLicenceAgreement.pdf
Size:
417.78 KB
Format:
Adobe Portable Document Format
Download

Collections

Cambridge University Research Outputs